Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 17/20 | 0.57 |
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19278111 | 0.93 | LNPEP (0.57) | LNPEPERAP2ERAP1HDAC1HDAC3 | |
| SCHEMBL17477801 | 0.91 | LNPEP (0.47) | LNPEPERAP2ERAP1HDAC1HDAC3 | |
| SCHEMBL17477813 | 0.91 | LNPEP (0.53) | LNPEPERAP2ERAP1HDAC1HDAC3 | |
| SCHEMBL17477796 | 0.85 | HDAC1 (0.45) | LNPEPHDAC1HDAC3HDAC2HDAC10 | |
| SCHEMBL17480676 | 0.84 | LNPEP (0.47) | LNPEPERAP2ERAP1HDAC1HDAC3 | |
| SCHEMBL17480686 | 0.79 | HDAC3 (0.48) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL17477806 | 0.76 | AAK1 (0.47) | LNPEPERAP2KDM4EKMT2A | |
| SCHEMBL17295758 | 0.76 | MEN1 (0.51) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL17295748 | 0.76 | MEN1 (0.47) | HDAC1HDAC3HDAC2HDAC10HDAC11 | |
| SCHEMBL17477792 | 0.75 | MEN1 (0.45) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180327-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10011585-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170240523-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3180327-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016018701-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240523-A1 | FACTOR XIa INHIBITORS | F11, SERPINC1, TFPI | LNPEP 1610/4885ERAP2 1507/4885ERAP1 1294/4885 |
| US-10011585-B2 | Factor XIa inhibitors | F11, SERPINC1, TFPI | LNPEP 1610/4885ERAP2 1507/4885ERAP1 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.